A 2026 Blueprint for Third-Party Risk Management in Life Sciences
One vendor gap. One inspection finding. One failed audit. The risk is no longer theoretical.
Life sciences organizations are under mounting pressure from the FDA, EMA, and global regulators to demonstrate continuous, auditable oversight of every CRO, CMO, cloud provider, and AI-enabled partner in their ecosystem. Yet most TPRM programs still rely on point-in-time assessments that are outdated the moment they’re completed.
The result: growing exposure, slower vendor onboarding, and inspection risk that keeps quality and compliance leaders up at night.
One global pharma company eliminated their assessment backlog, cut vendor evaluation cycle times significantly, and passed regulatory inspection with zero vendor-related findings. Here’s the framework they used.
Learn how leading life sciences organizations are modernizing vendor oversight. >>>
Why Your Current Approach May Not Be Enough
Regulators aren’t waiting. FDA Computer Software Assurance expectations, EMA supplier oversight requirements, GDPR vendor accountability, and NIS2 supply-chain obligations are converging — and they all point to the same conclusion: annual assessments are no longer sufficient.
This white paper gives quality, compliance, IT, and risk leaders a clear, defensible path forward
What You’ll Walk Away With
A practical, future-ready framework built specifically for regulated life sciences environments, including:
- The structural reasons traditional TPRM fails — and what to do instead
- How global regulators are redefining third-party accountability in 2026
- A four-phase operating model: Intelligence, Evaluation, Qualification, and Continuous Assurance
- How to build holistic vendor intelligence beyond cybersecurity questionnaires — covering compliance, financial stability, market position, and AI maturity
- A step-by-step approach to assessing AI-enabled vendors across data, model, and usage risks
- A real-world case study showing how a global pharma company transformed their vendor program and passed inspection with zero findings
Built for the Leaders Accountable for Vendor Risk
If you’re responsible for inspection readiness, vendor oversight, or operational resilience in a regulated organization — this is written for you.
Get the Blueprint >>>
About USDM Life Sciences
For over 25 years, USDM has helped pharmaceutical, biotech, and medical device companies navigate regulated digital transformation. Our TPRM Managed Service delivers continuous monitoring, SME-led qualification, and scalable execution — so your vendor program stays inspection-ready as your ecosystem grows.
Want to see how this applies to your organization? Request a conversation with our TPRM team.